Buchumschlag

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. Howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Röllig, Christoph (VerfasserIn) , Krämer, Alwin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Leukemia and lymphoma
Year: 2011, Jahrgang: 53, Heft: 6, Pages: 1062-1067
ISSN:1029-2403
DOI:10.3109/10428194.2011.637210
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.3109/10428194.2011.637210
Verlag, Volltext: https://doi.org/10.3109/10428194.2011.637210
Volltext
Verfasserangaben:Christoph Röllig, Christian Brandts, Shabnam Shaid, Marcus Hentrich, Alwin Krämer, Christian Junghanß, Eberhard Schleyer, Carsten Müller-Tidow, Wolfgang E. Berdel, Barbara Ritter, Karl-Heinz Pflüger, Michael Kramer, Martina Haibach, Gerhard Ehninger, Hubert Serve & Stefan W. Krause
Beschreibung
Zusammenfassung:Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. However, clinical data are still sparse, and there are only a few reported cases of monotherapy. The aim of the present research was to collect clinical data on efficacy and safety in a systematic way by conducting a survey on clinical experience with sorafenib. Thirty institutions were asked to document all patients treated with sorafenib diagnosed with AML. Of all 29 evaluable patients, six (21%) responded to sorafenib containing treatment by achieving a complete remission (CR, n = 2) or complete remission with incomplete platelet recovery (CRi, n = 4). In 23 patients receiving sorafenib as monotherapy, the CRi rate amounted to 13% and no CRs were documented. Of the 18 FLT-ITD positive patients with sorafenib monotherapy, two patients achieved a CRi (11%). In five FLT3-ITD negative cases, one CRi was documented (20%). Our results suggest the potential ability of the drug to induce remissions in refractory or relapsed AML even when given as monotherapy.
Beschreibung:Published online: 07 December 2011
Gesehen am 15.08.2018
Beschreibung:Online Resource
ISSN:1029-2403
DOI:10.3109/10428194.2011.637210

Ähnliche Einträge